Biohaven LTD 10-Q quarterly reports

Biohaven Ltd. reported a net loss of $137.3 million for the second quarter of 2026, with operating expenses decreasing overall due to strategic reprioritization, while key drug candidates show promising clinical data.

Biohaven Ltd. reported a net loss of $130.5 million for Q1 2026, with a significant decrease in R&D expenses driven by strategic program prioritization and lower share-based compensation.

Biohaven Ltd. reported a reduced net loss for the nine months ended September 30, 2025, but faced significant clinical trial failures and regulatory setbacks for key programs, leading to a strategic pipeline reprioritization.

Biohaven reports a net loss reduction, secures $250M in new debt, but faces clinical setbacks for key programs while advancing others.

Biohaven Ltd. announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and strategic collaborations.

Biohaven Ltd. released its third quarter 2024 financial results, highlighting progress in clinical trials and strategic platform advancements.

Biohaven Ltd. announced its second quarter 2024 financial results, highlighting significant R&D investments and progress across its clinical programs.

Biohaven Ltd. reported a net loss of $179.5 million for the first quarter of 2024, driven by a substantial increase in research and development expenses.